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Abstract
Objective The receptor MAS, encoded by Mas1, is expressed in microglia and its activation has been linked to anti-inflam-
matory actions. However, microglia are involved in several different processes in the central nervous system, including the 
promotion of angiogenesis. We therefore hypothesized that the receptor MAS also plays a role in angiogenesis via microglia.
Approach and results To assess the role of MAS on vascular network development, flat-mounted retinas from 3-day-old 
wild-type (WT) and  Mas1−/− mice were subjected to Isolectin B4 staining. The progression of the vascular front was reduced 
(− 24%, p < 0.0001) and vascular density decreased (− 38%, p < 0.001) in  Mas1−/− compared to WT mice with no change 
in the junction density. The number of filopodia and filopodia bursts were decreased in  Mas1−/− mice at the vascular front 
(− 21%, p < 0.05; − 29%, p < 0.0001, respectively). This was associated with a decreased number of vascular loops and 
decreased microglial density at the vascular front in  Mas1−/− mice (-32%, p < 0.001; − 26%, p < 0.05, respectively). As the 
front of the developing vasculature is characterized by reduced oxygen levels, we determined the expression of Mas1 follow-
ing hypoxia in primary microglia from 3-day-old WT mice. Hypoxia induced a 14-fold increase of Mas1 mRNA expression 
(p < 0.01). Moreover, stimulation of primary microglia with a MAS agonist induced expression of Notch1 (+ 57%, p < 0.05), 
Dll4 (+ 220%, p  < 0.001) and Jag1 (+ 137%, p < 0.001), genes previously described to mediate microglia/endothelial cell 
interaction during angiogenesis.
Conclusions Our study demonstrates that the activation of MAS is important for microglia recruitment and vascular growth 
in the developing retina.
Keywords Angiogenesis · Renin angiotensin system · Angiotensin receptors · Macrophage · CNS · Developmental 
biology · Endothelium · Vascular biology
Introduction
The development of the central nervous system (CNS) vas-
culature is a complex process driven by numerous signalling 
pathways and the interaction of different cell types. Beyond 
the contribution of mural cells that provide support and 
guidance to nascent vessels, microglia, the resident immune 
cells of the CNS, appear to play a key role in shaping the 
structure of the developing vasculature.
Microglia have been extensively studied in the context 
of brain injury and for their immune function as guardians 
of the CNS [1–3]; however, they appear to perform many 
other tasks, even in their “resting” state, such as monitoring 
neuronal activity, pruning, maturation and elimination of 
synapses as well as blood vessel formation [4, 5]. Micro-
glia role in vascular network formation has been corrobo-
rated by studies showing their involvement in the onset of 
vasculogenesis in human foetal retina at 10 weeks of ges-
tation before the development of the retinal vasculature 
and in growing sprouting vessels [6]. Furthermore, retinal 
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microglia depletion was associated with a reduced vascular 
development [4]. Throughout the developing retina, includ-
ing the tip and stalk cells of the vascular front, all endothelial 
cells appeared to be in intimate proximity of microglia [4]. 
Although cultured microglia are known to release growth 
factors and matrix metalloproteinases (MMP) of importance 
for endothelial cell proliferation and migration (e.g. VEGF, 
bFGF, MMP9 [7–11]), more studies are required to deci-
pher the exact molecular interactions between microglia and 
endothelial cells during vascular development.
The Renin Angiotensin System (RAS) is one of the major 
endocrine systems involved in the regulation of blood pres-
sure and fluid homeostasis. In addition, the RAS plays a 
major role during organogenesis, especially of the kidney 
and heart [12–14]. The RAS is also expressed in developing 
retinas in rats and in humans [15, 16]. Over the last dec-
ade, new RAS components have been identified. The ACE2 
enzyme, a homolog of ACE, can cleave Ang II into Ang-
(1–7). By binding to its receptor MAS (encoded by the Mas1 
gene), Ang-(1–7) mediates vasodilation, anti-proliferation, 
anti-fibrosis, apoptosis and anti-inflammation [17]. For these 
reasons, the ACE2/Ang-(1–7)/Mas axis is considered a so-
called “protective arm” of the RAS, in opposition to the 
actions mediated by the ACE/Ang II/AT1 axis [17, 18].
While previous studies have reported the anti-inflamma-
tory actions induced by activation of the receptor MAS in 
microglia [19], its role in angiogenesis remains controver-
sial. Although many studies centred on tumorigenesis have 
reported an anti-angiogenic role for the Ang-(1–7)/Mas axis 
[20–27], a few studies found that MAS promotes angiogen-
esis [28, 29]. Hoffman et al. recently showed that low doses 
of Ang-(1–7) induce tube formation of rat microvascular 
endothelial cells via MAS stimulation and subsequent acti-
vation of ERK1/2 [30]. In particular, in the CNS, Mas1 is 
expressed in both endothelial and microglia cells [31]. The 
high expression level of Mas1 during development suggests 
that it must be of importance in developmental stages but its 
role in neonatal vascularization has never been studied [31].
Here we show that neonatal retina from Mas1-deficient 
 (Mas1−/− ) mice has impaired vascular development and this 
is linked to reduced number of microglia at the front of the 
developing retinal vasculature. Both progression of vascular 
front and filopodia sprouting were decreased in retinas from 
 Mas1−/− as compared to wild-type (WT) mice. Remarka-
bly, the number of microglia at the vascular front was also 
decreased, whereas it did not change in other regions of the 
retinas. The region, in which the filopodia burst and the 
vascular front progresses, is highly hypoxic. We found that 
Mas1 is strongly upregulated in microglia in hypoxic condi-
tions. Stimulation of the receptor MAS with the non-peptide 
Ang-(1–7) analogue, AVE0991, resulted in the upregulation 
of Notch1, Delta-like ligand 4 (Dll4) and Jagged1 (Jag1) 
expression, members of Notch signalling pathway previously 
described to play a role in microglia recruitment at the sites 
of endothelial cell anastomosis during retinal angiogene-
sis [32]. Altogether, these results indicate a role for MAS 
in microglia/endothelial cell interaction for the growth of 
developing vascular network in the neonatal mouse retina.
Material and methods
Animals
Three-day-old Mas1-deficient  (Mas1−/−) mice and C57BL/6J 
wild-type (WT) mice were obtained from the Max Delbrück 
Center for Molecular Medicine, Berlin, Germany [33] and 
were sacrificed at postnatal day 3 for the study of retinas. For 
the isolation of primary microglia, 2–3-day-old C57BL/6J 
WT mice were obtained from BIOMED Research Institute, 
Hasselt University, Belgium. Animals were maintained 
under temperature-controlled conditions with an artificial 
12-h light/dark cycle and were allowed standard chow and 
water ad  libitum. All experimental protocols and meth-
ods involving animals within this study were conducted in 
accordance with institutional guidelines and approved by 
the Ethical Committees for Animal Experiments from Max 
Delbrück Center for Molecular Medicine, Berlin, and Has-
selt University.
Retina isolation and immunohistochemistry
Retinas were isolated from the eyeballs of 3-day-old WT and 
 Mas1−/− mice as previously described (n = 8) [34]. Isolectin 
B4 (IB4, from Griffonia simplicifolia, Alexa Fluor® 488 
conjugate, I21411, Thermo Fisher Scientific, 20 µg/ml) was 
used to stain blood vessels [35]. Microglia were stained with 
a rabbit polyclonal anti-Iba1 antibody (Ionized calcium-
Binding Adapter molecule 1, a specific microglia marker) 
(Wako 019-19741, 1:500) and secondary goat anti-rabbit 
AF568 antibody (Invitrogen A11036, 1:400). Retinas were 
flat-mounted with a drop of ProLong® Diamond Antifade 
Mountant (Thermo Fisher P36965). The vascular front was 
measured as the radius of the vascular network from the 
centre of the optic disc to the edge of the network, using 
low-magnification (× 2) pictures acquired with an EVOS-
FL microscope. To quantify the other vascular parameters, 
pictures were taken with a confocal Leica SPE microscope. 
Vascular density (calculated as percentage of the field of 
view stained by IB4) and junctions densities (calculated 
as the number of vessel junctions per  mm2) were obtained 
using ImageJ and Angiotool software [36], using 4–6 fields 
of views away from the vascular front, per retina at × 10 
and × 20 magnification, respectively. Filopodia density, 
filopodia burst densities, the number of sprouts, the aver-
age vascular sprout length and the number of vascular loops 
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(defined as anastomosis of vascular sprouts) at the vascular 
front were analysed from eight fields of views from 6 to 9 
retinas acquired at a × 63 magnification (x 175; y 175; z 
18 µm) [37]. Number of filopodia and number of sprouts 
were quantified per 100 µm vascular front length and number 
of filopodia bursts and number of vascular loops were quan-
tified per 0.03  mm2. Density of microglia was assessed in 
both avascular and vascular areas of WT and  Mas1−/− retinas 
(n = 12–14). Four z-stacks were acquired per retina (x 300; y 
300; z 18 µm) and were maximally projected to quantify the 
number of Iba1 positive cells per area.
Microglia isolation, immunocytochemistry, 
stimulation
Microglia cultures were prepared from postnatal P2-3 
C57BL/6J mouse pups and cultured as previously described 
[38]. Purity of microglial culture was assessed by IB4/
DAPI staining and revealed 91.0 ± 0.6%  IB4+ cells (data 
not shown). Microglia were stained for Iba1 with a rabbit 
polyclonal anti-Iba1 antibody (Wako 019-19741, 1:500) 
and secondary goat anti-rabbit AF568 antibody (Invitro-
gen A11036, 1/400). The expression of the receptor MAS 
was revealed using an anti-MAS antibody (AAR-013, Alo-
mone Labs, 1:20) and a secondary goat anti-rabbit antibody 
coupled to Alexa Fluor 568 (Invitrogen, A11036, 1:200) 
(Supplementary Fig. 1). Prior to RNA collection, microglia 
were exposed to the non-peptide MAS agonist (AVE 0991, 
ApexBio B1007, 1 µM, 24 h) or to hypoxia to mimic the 
absence of vasculature (1%  O2, 24 h).
Tube formation assay
Geltrex™ LDEV-Free Reduced Growth Factor Basement 
Membrane Matrix (ThermoFisher, A1413201) was used for 
tube formation assays with RF6/A cells (ATCC CRL-1780) 
in 96-well microplate (µ-Plate Angiogenesis 96 Well, ibidi®, 
89646) by following the manufacturer’s instructions. RF/6A 
cells are spontaneously immortalized endothelial cells 
derived from the choroid and retina of a rhesus macaque. 
RF/6A cells were cultured at 37 °C, in 5%  CO2 and 95% 
humidified air in EMEM (ATCC 30-2003) supplemented 
with 10% foetal bovine serum (FBS, Gibco) and 1% penicil-
lin/streptomycin (Gibco). Before the cells reach confluency, 
they were trypsinized, resuspended in EMEM + 0.5% FBS 
with the different conditions (PBS, VEGF 1 nM as positive 
control, Suramin 10 µM, an inhibitor of several growth fac-
tor receptors, as negative control or AVE0991 1 µM, non-
peptide MAS agonist) before seeding on Geltrex-coated 
wells (10 000 cells/well). At t = 6 h, cells were incubated 
with CellTracker™ Green CMFDA (Thermo Fisher Scien-
tific C7025, 15 µM) for 30 min before washing with PBS 
and imaging. Wells were imaged with Cytation 3 microplate 
reader (BioTek Instruments Inc.) using a × 4 objective and a 
GFP filter and tube formation analysis was performed with 
the AngioTool software [36].
Quantitative PCR
RNA was isolated from cells by using RNeasy micro kit 
Qiagen (Qiagen, GmbH, Hilden, Germany). DNA was syn-
thesized with Applied Biosystems High-Capacity cDNA 
Reverse Transcription Kit. Quantitative real-time PCR was 
performed on a Biorad CFX96 (Biorad, Veenendaal, The 
Netherlands). Primers are listed in Supplementary Table 1. 
The level of expression was normalized and expressed rela-
tively to control using the ΔΔCt method. Two experiments 
were performed per condition and PCR reactions were per-
formed in triplicate.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 
v6.0. Results are expressed as mean ± SEM. Unpaired two-
tailed t-tests were used to compare results from WT and 
 Mas1−/− groups. One-way ANOVA, followed by Tukey’s 
multiple comparison post-test was used to compare results 
from the tube formation assay experiments.
Results
Mas1 deficiency impairs retinal vasculature 
development
In order to study the role of MAS in developmental angio-
genesis, we performed Isolectin B4 (IB4) staining of retinal 
vasculature from 3-day-old  Mas1−/− mice (n = 8). We found 
that MAS deficiency was associated with decreased progres-
sion of the vascular front (− 24%, p < 0.0001) (Fig. 1a, b) 
and decreased vascular density (− 38%, p < 0.001) (Fig. 1c) 
without alteration of junction density (− 6%, p = 0.37) 
(Fig. 1d). Moreover, the densities of filopodia and filo-
podia bursts were decreased in absence of MAS (− 21%, 
p < 0.05; and − 29%, p < 0.0001, respectively) (Fig. 1e–g). 
There was no difference between groups in the average 
length of sprouts or the number of sprouts (+ 14%, p = 0.16 
and + 17%, p = 0.05, respectively) (Fig. 1h, i). The num-
ber of vascular loops at the vascular front was decreased in 
 Mas1−/− (− 32%, p < 0,001) (Fig. 1j).
MAS is important for microglia recruitment 
at the vascular front
The reduced growth of the vascular network was associ-
ated with a decreased microglial density at the vascular 
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front of  Mas1−/− mice (− 26%, p < 0.05), while micro-
glial density in the avascular area remained unchanged 
(p = 0.96) (Fig. 2a–c). Isolated microglia were positively 
stained by IB4 and expressed Iba1 and MAS (Supplemen-
tary Fig. 1). Microglia cells reacted to hypoxia by upregu-
lating Il-6 mRNA expression (eightfold change, p < 0.01) 
as well as Mas1 mRNA expression (14-fold change, 
p < 0.01) (Fig. 2d). Upon MAS stimulation with AVE0991, 
Il-10, Notch1, Dll4, and Jag1 mRNA expressions were 
upregulated (+ 67%, p < 0.05; + 57%, p < 0.05; + 220%, 
p < 0.001; + 137%, p < 0.001; respectively) (Fig. 2e).
MAS stimulation promotes the formation 
of endothelial tubes in vitro
The formation of tubes (capillary-like structures) by reti-
nal endothelial cells was enhanced by VEGF and the MAS 
agonist AVE0991 and abolished by Suramin treatment 
(Fig. 3a). Both the total tube length and number of junc-
tions were increased by VEGF (+ 35%, p < 0.05; + 64%, 
p < 0.01, respectively) and by AVE0991 (+ 37%, p < 0.05; 
+ 50%, p < 0.05, respectively)(Fig. 3b, c). Differently from 
what observed in microglia, stimulation of endothelial 
cells with AVE0991 did not affect Mas1, Vegfa, Notch1, 
Jag1 mRNA expressions (Fig. 3d).
Discussion
In this study, we show that MAS is required for microglia 
recruitment and blood vessel growth at the vascular front 
of developing retinas. The relative low oxygen concentra-
tion at the vascular front is a known driving force for the 
formation of new blood vessels in the developing retina 
[39]. The close positioning of microglia near endothelial 
tip cells and their exposure to low oxygen concentration 
has been shown to be of importance for the promotion of 
vascular sprouting under physiologic condition [4, 35]. 
In our study, hypoxic microglia upregulated the expres-
sion of Mas1, suggesting its importance for the function of 
microglia at the vascular front. In the absence of MAS, the 
number of filopodia and filopodia bursts were decreased, 
leading to a shorter vascular front and overall decreased 
vascular density. At the same time, the number of micro-
glia at the vascular front was decreased in  Mas1−/− mouse 
indicating a possible role for MAS in the migration of 
microglia towards the vascular front (Fig. 4).
Noteworthy, we found that stimulation of microglia 
with the MAS agonist AVE0991 induces the expression 
of Notch1 and its ligands Dll4 and Jag1. Notch signalling 
pathway has been reported to be important for microglia 
recruitment at the vascular front in the neonatal developing 
A B C D
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Fig. 1  Retinal vasculature in 3-day-old WT and  Mas1−/− mice (n = 8). 
Representative image of retinal vasculature stained with IB4 (green) 
(a, scale bar = 300 µm); Vascular front (b), vascular density (c) and 
junctions density (d); (n = 6–8). Representative pictures of vascular 
sprouts and filopodia at the vascular front (e; arrows: filopodia; yel-
low line: vascular front; white dots: filopodia bursts; stars: micro-
glia; scale bars = 20 µm); Filopodia density (f), filopodia burst densi-
ties (g), number of sprouts (h), average sprout length (i) and number 
of vascular loops (j) at the vascular front of retinas from WT and 
 Mas1−/− mice. *p < 0.05 versus WT
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retina [32], where microglia interact with sprouting 
endothelial cells to facilitate anastomosis between adja-
cent cells [4, 40]. Outtz et al. showed that recruitment 
of myeloid cells at the vascular front of  Notch1+/− mice 
was altered when compared to control [32]. Also, loss of 
Notch1 in myeloid lineage showed increased frequency 
of elongated tip endothelial cell sprout that failed to form 
anastomoses with their adjacent sprouts in the develop-
ing retinal vasculature [32]. In our study, the number 
of vascular loops at the vascular front was reduced in 
 Mas1−/− compared to WT and was associated with no 
change in number of sprouts in  Mas1−/−, corroborating 
the findings from Outtz et al.
Besides Notch1 upregulation, stimulation of microglia 
with AVE0991 resulted in the increased expressions of genes 
coding for Notch ligands, Dll4 and Jag1. The understand-
ing of Dll4 and Jag1 roles in microglia is limited. There are 
evidences pointing out a role for Notch1, Dll4 and Jag1 in 
macrophages and/or microglia in the context of inflamma-
tion. While Dll4 seems involved in macrophage differen-
tiation [41], Notch1 and Jag1 expressions were increased 
in activated microglia similarly to our study. Furthermore, 
antibody-mediated depletion of Notch1 in microglia 
decreased the expression of pro-inflammatory cytokines as 
well as the expression of colony stimulating factor 1 (CSF1), 
a growth factor required for the proliferation, differentiation 
and survival of macrophages and microglia [42]. This latter 
finding, together with the increased Notch1 expression medi-
ated by MAS stimulation in our study, lets us suggest that 
the decreased microglial density at the vascular front may 
also result from a decreased release of CSF1 by microglia 
in  Mas1−/− mice.
In addition, endothelial tip cells have been described to 
have low Notch signal, whereas their neighbour stalk cells 
show high Notch signal. However, tip cells continuously 
swap their positions, allowing stalk cells to become tip 
cells and vice versa [43, 44]. Therefore, it is reasonable to 
speculate that microglial Jag1 would activate Notch in the 
tip cells, providing a mechanism for the tip cells to become 
stalk cells, allowing other endothelial tip cells to take the 
lead for the progression of sprouting process and vascular 
network growth.
Upon exposure to hypoxia, microglia acquired a pro-
inflammatory phenotype with an increased Il-6 expression 
A B
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C
Fig. 2  Retinal microglial densities. Vasculature (IB4) and micro-
glia (Iba1) at the vascular front of retinas from 3-day-old WT and 
 Mas1−/− mice (a); microglial density in an avascular area (b) and at 
the vascular front (c); (n = 5–9). Il-6 and Mas1 mRNA expressions 
by primary microglia during hypoxia (d); Il-10, Notch1, Dll4 and 
Jag1 mRNA expressions in microglia treated with a MAS agonist 
(AVE0991, 1 µM) (e); (n = 2 experiments, triplicates). *p < 0.05 ver-
sus WT
486 Angiogenesis (2019) 22:481–489
1 3
as expected [45], whereas the activation of the receptor 
MAS led to the upregulation of the anti-inflammatory 
cytokine Il-10, as previously demonstrated [19]. The anti-
inflammatory and pro-angiogenic effect associated with 
MAS signalling may constitute a key mechanism to protect 
the CNS from injuries. In fact, it has been shown that the 
stimulation of the Ang-(1–7)/Mas axis is cerebroprotective 
in the context of stroke by increasing the brain capillary 
density via the activation of an eNOS/NO/VEGF signal-
ling [29]. In diabetic animal models, a recent study has 
shown an imbalance between Ang II and Ang-(1–7) in the 
diabetic eyes [45]. While in the non-diabetic eyes, Ang-
(1–7) has a wider distribution than Ang II, its intensity and 
distribution were both reduced in diabetic animals [45]. 
This study showed additionally that the pharmacological 
inhibition of ACE with captopril could reverse this imbal-
ance and suggests that increasing the endogenous expres-
sion of Ang-(1–7) could be beneficial in the context of 
diabetic retinopathy [46]. Another recent study has shown 
that low doses of Ang-(1–7) induce tube formation of rat 
microvascular endothelial cells [30]. Similarly, we found 
that stimulation of endothelial cells with the MAS agonist 
AVE0991 induces retinal endothelial cells to form tubes 
and this was observed in the absence of the regulation of 
Mas1, Vegfa, Notch1 and Jag1. Of note, while the Ang-
(1–7)/Mas axis has been often described for having similar 
functions than the Ang II/ Ang II receptor type 2  (AT2) 
axis, the second key player of the protective RAS [47], 
we did not observe changes in the retinal vasculature of 
 AT2−/− mice (data not shown).
Fig. 3  Impact of MAS stimulation on retinal endothelial cells in vitro. 
Tube formation assay with RF/6A cells (a–c) treated with PBS, 
VEGF (1  nM), Suramin (SUR, 10  µM) or a MAS receptor agonist 
(AVE0991, 1 µM). Representative pictures (a, scale bar = 200 µm); 
Quantification of total tube length (b) and junctions density (c) 
(n = 6–8); One-way ANOVA, followed by Tukey’s multiple compari-
sons post-test (*p < 0.05 vs. PBS; $p < 0.05 vs. VEGF). Mas1, Vegfa, 
Notch1 and Jag1 mRNA expressions in RF/6A cells treated with a 
MAS agonist (AVE0991, 1 µM) (d); (n = 2 experiments, triplicates)
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We found that MAS stimulation induces expression of 
Notch signalling members in microglia, but not endothe-
lial cells. We can however not draw conclusions on the 
impact of hypoxia on Notch signalling in the absence of 
MAS. Deeper insights into the interaction between MAS 
and Notch signalling pathways could provide new and 
more effective therapeutic strategies to contain pathologi-
cal NOTCH-stimulated angiogenesis, in diseases such as 
cancer or diabetic retinopathy.
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